Quantum Biopharma (QNTM) files Form 6-K with Q3 2025 financials

Rhea-AI Filing Summary

Quantum Biopharma Ltd. has furnished a Form 6-K that provides investors with access to its unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2025 and 2024, attached as Exhibit 99.1.

The filing also includes Management’s Discussion and Analysis of Financial Condition and Results of Operations for the same periods as Exhibit 99.2, CEO and CFO certificates, and full Inline XBRL files. These materials are incorporated by reference into the company’s existing Form F-3 registration statement.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of: November 2025

Commission File Number: 001-39152

Quantum Biopharma Ltd.

(Translation of registrant’s name into English)

1 Adelaide Street East, Suite 801

Toronto, Ontario M5C 2V9

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒     Form 40-F ☐

 INCORPORATION BY REFERENCE

This Report on Form 6-K and the exhibits attached hereto (Exhibit 99.1 and 99.2) are incorporated by reference into the Registrant’s Registration Statement on Form F-3 (SEC File No. 333-276264), including any prospectuses forming a part of such Registration Statement and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

1

CONTENTS

This Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) consists of Quantum BioPharma Ltd.’s (i) Unaudited Condensed Consolidated Financial Statements as of, and for the three and nine months ended September 30, 2025 and 2024, which are attached hereto as Exhibit 99.1; and (ii) Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three and nine months ended September 30, 2025 and 2024 , which is attached hereto as Exhibit 99.2.

2

EXHIBIT INDEX

Exhibit		Description
99.1		Condensed consolidated interim financial statements for the three and nine months ended September 30, 2025 and 2024
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operation for the three and nine months ended September 30, 2025 and 2024
99.3		CEO Certificate
99.4		CFO Certificate
101.INS		XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.SCH		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document
104		Cover Page Interactive Data File( formatted as Inline XBRL and contained in Exhibit 101)

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Quantum Biopharma Ltd. (Registrant)
Date: November 6, 2025	By:	/s/ Donal Carroll
		Donal Carroll, Chief Financial Officer

4

FAQ

What does Quantum Biopharma (QNTM) disclose in its latest Form 6-K?

Quantum Biopharma’s Form 6-K furnishes updated quarterly information for investors. It consists of unaudited condensed consolidated financial statements and a Management’s Discussion and Analysis for the three and nine months ended September 30, 2025 and 2024, together with related certifications and XBRL data.

Which financial periods are covered in Quantum Biopharma (QNTM) Q3 2025 materials?

The materials cover the three and nine months ended September 30, 2025 and 2024. Unaudited condensed consolidated financial statements and accompanying Management’s Discussion and Analysis for these comparative periods are attached as Exhibits 99.1 and 99.2 to the Form 6-K filing.

How is the Quantum Biopharma (QNTM) Form 6-K used in its Form F-3 registration?

The Form 6-K and attached exhibits are incorporated by reference into Quantum Biopharma’s Form F-3 registration statement. This means the unaudited financial statements, MD&A, and related materials become part of the disclosure package available under that shelf registration.

What exhibits accompany Quantum Biopharma (QNTM) Form 6-K for Q3 2025?

Key exhibits include unaudited condensed consolidated interim financial statements (Exhibit 99.1) and Management’s Discussion and Analysis (Exhibit 99.2). Additional exhibits provide CEO and CFO certificates and a full Inline XBRL suite, including instance, schema, calculation, definition, label, and presentation linkbase documents.

Are Quantum Biopharma (QNTM) Q3 2025 financial statements audited or unaudited?

The financial statements furnished with this Form 6-K are unaudited condensed consolidated interim statements. They relate to the three and nine months ended September 30, 2025 and 2024 and are presented together with a Management’s Discussion and Analysis for those periods.

What type of issuer is Quantum Biopharma (QNTM) under this Form 6-K?

Quantum Biopharma files as a foreign private issuer under the Securities Exchange Act. Its Form 6-K is a Report of Foreign Private Issuer, used to furnish interim information such as quarterly financial statements and MD&A to U.S. investors and regulators.